JAMA Oncology

JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

Publisher
JAMA

Some content from Wikipedia, licensed under CC BY-SA

Oncology & Cancer

Multigene testing for all breast cancer patients cost-effective

(HealthDay)—Unselected, multigene testing for all patients with breast cancer would be cost-effective in the United Kingdom and the United States, according to a study published online Oct. 3 in JAMA Oncology.

Oncology & Cancer

Higher mortality seen for male breast cancer patients

(HealthDay)—Male breast cancer patients have higher mortality after cancer diagnosis than female patients, according to a study published online Sept. 19 in JAMA Oncology.

Oncology & Cancer

Study examines cancer-care outcomes among US hospitals

Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available ...

page 1 from 34